High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Stopped early · Phase 1/Phase 2

Conditions studied: Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma

In brief

The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

Key facts

Study ID

NCT03901573

Run by

NeoImmuneTech

People needed

31

Starts

2019-12-26

Expected to finish

2023-08-15

Last updated by the study team

2025-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Duarte, California, United States
• Northwestern University — Chicago, Illinois, United States
• Dana Farber — Boston, Massachusetts, United States
• MGH — Boston, Massachusetts, United States
• Washington University — St Louis, Missouri, United States
• Mt Sinai — New York, New York, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Providence Portland Medical Center — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.